PMID- 21075775
OWN - NLM
STAT- MEDLINE
DCOM- 20111209
LR  - 20220409
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 32
IP  - 2
DP  - 2011 Jan
TI  - One year follow-up of the multi-centre European PARTNER transcatheter heart valve 
      study.
PG  - 148-57
LID - 10.1093/eurheartj/ehq427 [doi]
AB  - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has emerged as a new 
      therapeutic option in high-risk patients with severe aortic stenosis. AIMS: 
      PARTNER EU is the first study to evaluate prospectively the procedural and 
      mid-term outcomes of transfemoral (TF) or transapical (TA) implantation of the 
      Edwards SAPIEN(R) valve involving a multi-disciplinary approach. METHODS AND 
      RESULTS: Primary safety endpoints were 30 days and 6 months mortality. Primary 
      efficacy endpoints were haemodynamic and functional improvement at 12 months. One 
      hundred and thirty patients (61 TF, 69 TA), aged 82.1 +/- 5.5 years were included. 
      TA patients had higher logistic EuroSCORE (33.8 vs. 25.7%, P = 0.0005) and more 
      peripheral disease (49.3 vs. 16.4%, P< 0.0001). Procedures were aborted in four 
      TA (5.8%) and six TF cases (9.8%). Valve implantation was successful in the 
      remaining patients in 95.4 and 96.4%, respectively. Thirty days and 6 months 
      survival were 81.2 and 58.0% (TA) and 91.8 and 90.2% (TF). In both groups, mean 
      aortic gradient decreased from 46.9 +/- 18.1 to 10.9 +/- 5.4 mmHg 6 months post-TAVI. 
      In total, 78.1 and 84.8% of patients experienced significant improvement in New 
      York Heart Association (NYHA) class, whereas 73.9 and 72.7% had improved Kansas 
      City Cardiomyopathy Questionnaire (KCCQ) scores in TA and TF cohorts, 
      respectively. CONCLUSION: This first team-based multi-centre European TAVI 
      registry shows promising results in high-risk patients treated by TF or TA 
      delivery. Survival rates differ significantly between TF and TA groups and 
      probably reflect the higher risk profile of the TA cohort. Optimal patient 
      screening, approach selection, and device refinement may improve outcomes.
FAU - Lefevre, Thierry
AU  - Lefevre T
AD  - Institut Hospitalier Jacques Cartier, 6 avenue du Noyer Lambert, Massy, France. 
      t.lefevre@icps.com.fr
FAU - Kappetein, Ari Pieter
AU  - Kappetein AP
FAU - Wolner, Ernst
AU  - Wolner E
FAU - Nataf, Patrick
AU  - Nataf P
FAU - Thomas, Martyn
AU  - Thomas M
FAU - Schachinger, Volker
AU  - Schachinger V
FAU - De Bruyne, Bernard
AU  - De Bruyne B
FAU - Eltchaninoff, Helene
AU  - Eltchaninoff H
FAU - Thielmann, Matthias
AU  - Thielmann M
FAU - Himbert, Dominique
AU  - Himbert D
FAU - Romano, Mauro
AU  - Romano M
FAU - Serruys, Patrick
AU  - Serruys P
FAU - Wimmer-Greinecker, Gerhard
AU  - Wimmer-Greinecker G
CN  - PARTNER EU Investigator Group
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20101112
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve/*surgery
MH  - Aortic Valve Stenosis/mortality/*surgery
MH  - Cardiac Catheterization/*methods/mortality
MH  - Cause of Death
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*methods/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC3021390
FIR - Baumgartner, H
IR  - Baumgartner H
FIR - Glogar, D
IR  - Glogar D
FIR - Kasimir, M T
IR  - Kasimir MT
FIR - Simon, P
IR  - Simon P
FIR - Wisser, W
IR  - Wisser W
FIR - Wolner, E
IR  - Wolner E
FIR - Al-Attar, N
IR  - Al-Attar N
FIR - Himbert, D
IR  - Himbert D
FIR - Nataf, P
IR  - Nataf P
FIR - Vahanian, A
IR  - Vahanian A
FIR - El-Gamel, A
IR  - El-Gamel A
FIR - MacCarthy, P
IR  - MacCarthy P
FIR - Thomas, M
IR  - Thomas M
FIR - Wendler, O
IR  - Wendler O
FIR - Eggebrecht, H
IR  - Eggebrecht H
FIR - Erbel, R
IR  - Erbel R
FIR - Jakob, H
IR  - Jakob H
FIR - Kahlert, P
IR  - Kahlert P
FIR - Sack, S
IR  - Sack S
FIR - Thielmann, M
IR  - Thielmann M
FIR - Wendt, D
IR  - Wendt D
FIR - Donzeau-Gouge, P
IR  - Donzeau-Gouge P
FIR - Farge, A
IR  - Farge A
FIR - Lefevre, T
IR  - Lefevre T
FIR - Morice, M-C
IR  - Morice MC
FIR - Romano, M
IR  - Romano M
FIR - Casselman, F
IR  - Casselman F
FIR - De Bruyne, B
IR  - De Bruyne B
FIR - Degrieck, I
IR  - Degrieck I
FIR - Vanderheyden, Marc
IR  - Vanderheyden M
FIR - Vanermen, H
IR  - Vanermen H
FIR - Bessou, J-P
IR  - Bessou JP
FIR - Cribier, A
IR  - Cribier A
FIR - Eltchaninoff, H
IR  - Eltchaninoff H
FIR - Litzler, Y-P
IR  - Litzler YP
FIR - Doss, M
IR  - Doss M
FIR - Fichtlscherer, S
IR  - Fichtlscherer S
FIR - Schachinger, V
IR  - Schachinger V
FIR - Wimmer-Greinecker, G
IR  - Wimmer-Greinecker G
FIR - DeJaegere, P
IR  - DeJaegere P
FIR - Kappetein, A P
IR  - Kappetein AP
FIR - Serruys, P
IR  - Serruys P
EDAT- 2010/11/16 06:00
MHDA- 2011/12/14 06:00
PMCR- 2010/11/12
CRDT- 2010/11/16 06:00
PHST- 2010/11/16 06:00 [entrez]
PHST- 2010/11/16 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
PHST- 2010/11/12 00:00 [pmc-release]
AID - ehq427 [pii]
AID - 10.1093/eurheartj/ehq427 [doi]
PST - ppublish
SO  - Eur Heart J. 2011 Jan;32(2):148-57. doi: 10.1093/eurheartj/ehq427. Epub 2010 Nov 
      12.